New drug with chemotherapy for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a new drug called QL1706 to standard chemotherapy (two common cancer drugs) works better for advanced esophageal cancer that can't be surgically removed. The goal is to see if this combination helps patients live longer and controls the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced or metastatic esophageal squamous cell carcinoma (a specific type of esophageal cancer) confirmed by biopsy
- You have never received chemotherapy or immunotherapy for this cancer before
- You are between 18 and 75 years old and in good enough health to handle treatment (able to do light activity)
- Your organs (liver, kidneys, heart, blood counts) are working well enough based on recent blood tests
- You are willing to use birth control during the study and for 3 months after if you can have children
- You don't have other serious health conditions like heart failure, active infections, or other cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment approach for patients with advanced esophageal cancer whose disease progressed or didn't respond to initial chemotherapy and immunotherapy. The goal is to see if this new treatment can help shrink tumors and improve outcomes for patients who cannot have surgery.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a combination of two drugs, QL1706 and celecoxib, in people with advanced esophageal cancer that has worsened after prior immunotherapy. The goal is to see if this new combination can help shrink tumors or slow disease progression.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery for a certain type of esophageal cancer. The goal is to see if the combination works better than chemotherapy alone at shrinking the tumor and improving surgery outcomes.
This trial tests a new combination of drugs (QL1706 and lenvatinib) for people with advanced esophageal cancer that has stopped responding to standard immunotherapy. The goal is to see if this new treatment can help shrink tumors or slow the cancer's growth.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new QL1706 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.